Pneumocare

Pneumocare is conducting studies that target atherosclerotic cardiovascular disease, high blood pressure, and lipid abnormalities to improve long‑term heart health and reduce the risk of major cardiac events.

• Atherosclerotic Cardiovascular Disease (ASCVD)
• Hypertension
• Elevated Lipoprotein(a)
• Hypertriglyceridemia and severe hypertriglyceridemia
• High cardiovascular risk populations

The trials evaluate novel therapies and risk‑reduction strategies, aiming to lower cardiovascular mortality and improve patient outcomes.

Research at the site includes multiple investigations of asthma and chronic obstructive pulmonary disease, focusing on reducing exacerbations and enhancing lung function for patients with persistent symptoms.

• Severe and uncontrolled asthma
• Eosinophilic asthma phenotypes
• Chronic Obstructive Pulmonary Disease (COPD)
• Refractory or unexplained chronic cough
• Respiratory syncytial virus (RSV) infections in older adults

The goal is to test new biologics and inhaled treatments that can lessen flare‑ups and improve quality of life for respiratory patients.

The clinic is evaluating therapies for sleep‑related neurological conditions such as narcolepsy and idiopathic hypersomnia, seeking to alleviate excessive daytime sleepiness and improve daily functioning.

• Narcolepsy Type 1 (with cataplexy)
• Narcolepsy Type 2
• Idiopathic Hypersomnia
• Obstructive sleep apnea (OSA) interventions

These trials assess safety and efficacy of emerging agents designed to restore normal wakefulness cycles.

Studies at Pneumocare explore disorders that affect brain‑stem regulation, including excessive daytime sleepiness linked to narcolepsy and hypersomnia, to identify treatments that stabilize alertness.

• Narcolepsy with cataplexy
• Idiopathic hypersomnia
• Obstructive sleep apnea

The research aims to provide patients with reliable therapeutic options that reduce daytime fatigue.

The site’s metabolic program focuses on disorders of lipid metabolism, such as hypertriglyceridemia, to evaluate agents that can lower triglyceride levels and mitigate cardiovascular risk.

• Severe hypertriglyceridemia (SHTG)
• Elevated triglyceride levels
• Metabolic syndrome components

Trials are designed to assess both efficacy and long‑term safety of lipid‑lowering therapies.

Research includes investigations of chronic sinus and nasal conditions, targeting chronic rhinosinusitis with and without nasal polyps and perennial allergic rhinitis to improve nasal airflow and symptom control.

• Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
• Chronic Rhinosinusitis without Nasal Polyps (CRSsNP)
• Perennial Allergic Rhinitis (PAR)

The studies evaluate biologic agents and intranasal therapies aimed at reducing inflammation and polyp size.

Pneumocare participates in vaccine and antiviral research for COVID‑19, influenza, and respiratory syncytial virus, seeking to protect high‑risk populations and reduce severe disease outcomes.

• COVID‑19 in high‑risk adults
• High‑dose influenza vaccine efficacy in seniors
• RSV and human metapneumovirus (hMPV) vaccine trials

These trials assess immunogenicity, safety, and real‑world effectiveness of next‑generation vaccines.

The facility conducts a pediatric study on erosive esophagitis, examining maintenance therapy to sustain healing and prevent recurrence of esophageal injury.

• Erosive esophagitis in children aged 1‑11 years

The objective is to confirm long‑term safety and effectiveness of oral proton‑pump inhibitor treatment.

Investigations into immune modulation focus on novel biologics that target key cytokine pathways, aiming to reduce inflammation in respiratory and sinus diseases.

• Anti‑TSLP therapy for asthma control
• IL‑5/IL‑4R antagonists for eosinophilic inflammation
• Broad‑spectrum immune modulators for COPD exacerbations

These studies explore how altering immune system phenomena can translate into clinical benefit across multiple disease areas.